Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
· Clinical trial combining mocetinostat with pembrolizumab and guadecitabine in NSCLC now open and enrolling patients · Enrollment continues in Mirati-sponsored clinical trial of mocetinostat combined with durvalumab in checkpoint refractory NSCLC; first cohort expands to stage 2. SAN DIEGO , Oct.
View HTML
Toggle Summary Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , Sept. 19, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26 th at 1:40 p.m. ET / 10:40 a.m. PT .
View HTML
Toggle Summary Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer
- Combination of sitravatinib and nivolumab in NSCLC patients with documented progression following checkpoint therapy demonstrated 3 confirmed Partial Responses in first 11 evaluable patients - First evaluable NSCLC patient with CBL inactivating mutation treated with single agent sitravatinib
View HTML
Toggle Summary Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer
SAN DIEGO , Sept. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will highlight data on sitravatinib at the IASLC 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in
View HTML
Toggle Summary Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference
SAN DIEGO , Aug. 30, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will participate in a panel discussion, "I/O Beyond PD-1: Opportunities & Challenges" at the 2017 Citi Biotech Conference in Boston on Wednesday, September 6
View HTML
Toggle Summary Mirati Therapeutics Reports Second Quarter 2017 Financial Results
SAN DIEGO , Aug. 3, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported financial results for the second quarter 2017. "The second half of 2017 remains on track to be a significant time for all of Mirati's programs," said Charles
View HTML
Toggle Summary Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York
SAN DIEGO, July 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, announced today that they will host a Key Opinion Leader breakfast on the topic of Immuno-Oncology combinations on Tuesday, July 11 at 8:00am
View HTML
Toggle Summary Mirati Therapeutics Announces Appointment Of Neil Reisman To The Board Of Directors View HTML
Toggle Summary Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics Reports First Quarter 2017 Financial Results View HTML